Amarin Corporation (AMRN) is a Likely Beneficiary From Teva Ruling, Citi Reiterates Buy
Tweet Send to a Friend
Citi analyst Joel Beatty reiterated a Buy rating and $12.00 price target on Amarin Corporation (NASDAQ: AMRN) after a U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
